(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 14 January 2010 (14.01.2010) WO 2010/005480 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/519 (2006.01) Λ61K 47/32 (2006.01) kind of national protection available): AE, AG, AL, AM, T9/00 (2006.01) A61K 47/26 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 9/48 (2006.01) A61P 9/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 6 T9/20 (2006.01) A61P 7/00 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (21) International Application Number: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, PCT/US2009/003632 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (22) International Filing Date: NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, 16 June 2009 (16.06.2009) SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, 61/132,429 16 June 2008 (16.06.2008) US ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, 61/209,056 2 March 2009 (02.03.2009) US TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, 0905567.4 3 1 March 2009 (3 1.03.2009) GB ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), (71) Applicant (for all designated States except US): BIO- OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, VASCULAR, INC. [US/US]; 12230 El Camino Real, MR, NE, SN, TD, TG). Suite 100, San Diego, CA 92130 (US). Declarations under Rule 4.17: (72) Inventors; and — as to the applicant's entitlement to claim the priority of (75) Inventors/Applicants (for US only): GLIDDEN, Paul, the earlier application (Rule 4.1 7(Hi)) F. [US/US]; 12205 Briar Knoll Way, San Diego, CA 92128 (US). PILGRIM, Alison, J . [GB/US]; 765 1 Published: Country Club Drive, La Jolla, CA 92037 (US). HAN¬ — without international search report and to be republished SON, Stephen, R . [US/US]; 16922 N.W. Hazelgrove upon receipt of that report (Rule 48.2(g)) Court, Beaverton, OR 97006 (US). (74) Agents: POTTER, Karen, G . et al; K & L Gates LLP, 3580 Carmel Mountain Road, Suite 200, San Diego, CA 92130 (US). (54) Title: CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR (57) Abstract: Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-oc- clusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided. CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR RELATED APPLICATIONS Benefit of priority is claimed to U.S. Provisional Application Serial No. 61/132,429, filed June 16, 2008, entitled "CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR;" and U.S. Provisional Application Serial No. 61/209,056, filed March 2, 2009, entitled "CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR," each to Paul F. Glidden, Alison J. Pilgrim and Stephen R. Hanson; and to United Kingdom Patent Application Serial No 09 05567.4, filed March 31, 2009, entitled "CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR," which claims priority to U.S. Provisional Application Serial Nos. 61/124,277 and 61/124,330. This application is related to U.S. Application Serial No. (Attorney Dkt. No. 0 11955-00013/5203), filed June 16, 2009, entitled "CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR," which also claims priority to U.S. Provisional Application Serial Nos. 61/124,277 and 61/124,330 and to United Kingdom Patent Application Serial No 09 05567.4. Where permitted, the subject matter of each of the above-referenced applications is incorporated by reference in its entirety. FIELD OF THE INVENTION Compositions and methods for reducing circulating platelet number in a subject and for the treatment and/or prevention of platelet-related conditions, diseases and/or disorders or other diseases and disorders are provided. BACKGROUND Conditions resulting from thrombotic or thromboembolic events are leading causes of illness and death in adults in western civilization. Platelets play a role in the etiology of several thrombotic and other vaso-occlusive disorders. A great deal of effort and monetary resources have been directed towards understanding the mechanisms involved in vascular occlusive diseases involving thrombotic or thromboembolic events. These efforts have yielded a number therapeutic agents. Notwithstanding the effort and financial resources that have been invested, these conditions still account for the vast majority of illness and death in the adult populations of developed nations. Thus, a need exists for compositions and methods for treatment and/or prevention of platelet related conditions or disorders, including hematological proliferative disorders, myeloproliferative disorders and thrombotic and other vaso-occlusive disorders. Accordingly, among the objects herein, it is an object to provide compositions and methods for treatment and/or prevention of platelet related conditions or disorders, including hematological proliferative disorders, myeloproliferative disorders and thrombotic and other vaso-occlusive disorders. SUMMARY Provided herein are compositions and prophylactic and therapeutic methods for reducing circulating platelet number in a subject and for the treatment and/or prevention of platelet-related conditions, diseases and/or disorders or other diseases and disorders. Provided herein is a composition that includes a solid support core of a substantially water soluble, swellable or insoluble material; an optional preparatory coat, where the preparatory coat is from 0-5% by weight of the composition; a substrate layer that includes a binder and 50 µg to 10 mg of microparticles of a platelet number reducing agent, where the platelet-reducing agent is present in a form that has a shelf stability of at least three months, the binder is present at a weight of 0.1-5% by weight of the composition and at least 90% of the microparticles are 25 microns or less; a release control component effective for controlled release of the platelet number reducing agent, where the release control component is present at a weight of 0-10 % by weight of the composition; and an optional finishing coat and/or enteric coating, where the finishing coat and/or enteric coating is present at a weight of 0-10 % by weight of the composition. In some embodiments, the composition further includes a seal coat layer including a substantially water-soluble polymer on the substrate layer, where the seal coat is disposed between the substrate layer and the release control component and the seal coat reduces chemical interaction between the platelet reducing agent and the release control component and/or the platelet reducing agent and the optional finishing coat. In some embodiments, the seal coat, when present, is present at a weight of 0.1-10 % by weight of the composition, particularly at a weight of 1-5% by weight of the composition. Also provided are compositions that include (i) a solid support core of a substantially water soluble, swellable or insoluble material; (ii) an optional preparatory coat, where the preparatory coat is from 0-5% by weight of the composition; (iii) a substrate layer including a binder and 50 µg to 10 mg of microparticles of a platelet number reducing agent, where (a) the binder is present at a weight of 0.1-5% by weight of the composition, (b) at least 90% of the microparticles are 25 microns or less and (c) the platelet-reducing agent is in form that has a shelf stability of at least 3 months; (iv) a release control component effective for controlled release of the platelet number reducing agent, where the release control component is present at a weight of 0-10 % by weight of the composition; (v) a seal coat layer that includes a substantially water-soluble polymer, where the seal coat is present at a weight of 0-10 % by weight of the composition; and (vi) an optional finishing coat and/or enteric coating, where the finishing coat and/or enteric coating is present at a weight of 0-10 % by weight of the composition; where the seal coat is disposed between the substrate layer and the release control component and the seal coat reduces chemical interaction between the platelet reducing agent and the release control component and/or the platelet reducing agent and the optional finishing coat. The substrate layer can include from 10 ng to 10,000 µg of microparticles of a platelet number reducing agent. The amount of microparticles in the substrate layer can vary depending on the platelet reducing agent and can be present in an amount of between 50 µg to 5000 µg of microparticles, or 150 µg to 500 µg of microparticles or 200 µg to 400 µg of microparticles of a platelet number reducing agent.